Historical record - last NADAC effective date: 3/23/2016
Product Information
SOVALDI 400 MG TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $975.3000 per EA under NDC 61958150101. Its NADAC has been published 152 times since Mar 19, 2014.
FDA first approved this application on Dec 6, 2013.
Strength
400 mg/1
Manufacturer
Gilead Sciences, Inc.NDC
61958150101
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
3/23/2016
Active Ingredients
SOFOSBUVIRApproval Type
New Drug (NDA)
FDA Application
NDA204671FDA Approved
12/6/2013
On Market Since
12/6/2013
Pharmacological Classes
Price Statistics
The NADAC for SOVALDI 400 MG TABLET has been published 152 times since Mar 19, 2014, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $975.3000 per EA |
|---|---|
| All-time high | $981.5000 (Jan 13, 2016) |
| All-time low | $961.6000 (Mar 19, 2014) |
| Median price | $975.3000 |
| Average price | $974.5771 |
| Largest weekly change | +1.7% (Jan 14, 2015) |
| Weeks tracked | 152 |
| Tracking since | Mar 19, 2014 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+1.4%
Last surveyed Apr 12, 2017 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the SOFOSBUVIR market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Gilead Sciences, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
SOFOSBUVIR market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SOVALDI 400 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SOVALDI 400 MG TABLET, manufactured by Gilead Sciences, Inc., is $975.3000 per EA (NDC 61958150101), effective Apr 12, 2017.
How has the price of SOVALDI 400 MG TABLET changed over time?
Over the history we have for it, the NADAC for SOVALDI 400 MG TABLET has held within roughly two percent of its current level. It has been tracked across 152 weekly CMS publications since Mar 19, 2014.
What are the highest and lowest recorded NADAC prices for SOVALDI 400 MG TABLET?
Since Mar 19, 2014, the NADAC for SOVALDI 400 MG TABLET has ranged from a low of $961.6000 (Mar 19, 2014) to a high of $981.5000 (Jan 13, 2016), with a median of $975.3000 per EA.
Are there cheaper alternatives to SOVALDI 400 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of SOVALDI 400 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SOVALDI 400 MG TABLET?
SOVALDI 400 MG TABLET (NDC 61958150101) is labeled by Gilead Sciences, Inc., and CMS classifies it as a brand product.